Some Teva Comments:
As you know we appealed to the U.S. Supreme Court in our Copaxone patent litigation. Arguments were held on October 15th. We raised strong argument which basically focused on the proper standard of review to be applied in patent claim construction. While it is not possible to predict how the Supreme Court will decide things, we’re optimistic that the Supreme Court will rule in our favor and overturn the decision of the federal circuit. With the Supreme Court rule in our favor it will probably send the case back to the federal circuit to decide it again based on correct standards. There is no set time for the Supreme Court decision but we generally expect it to come late this year or Q1, FDA decision on our most recent CP citizen petition, expected by late November 2014.
========================================================================
I would like to ask now Mike Derkacz, Vice President and General Manager U.S. Teva CNS to share with us why we believe we’re on-track to achieve 65% conversion rate by year-end without generic Copaxone.
It is my pleasure to report that the Copaxone 40 milligram conversion continues to progress as planned. As of October 17th, Copaxone 40 milligram is 57.4% of TRXs of the Copaxone franchise. And even more importantly 40 milligram new-to-brand prescriptions now account for 80% of the Copaxone franchise. This is a very important leading indicator and a very reliable metric, as it truly represents new-to-brand patients.
========================================================================
Introduction of an AB-rated generic competition to Copaxone before the end of this year could reduce operating income by 40 million to 50 million per month and depending on a possible entry.
Same Old. But what would you expect them to say.
